Irinotecan liposome combined with bevacizumab
Phase 2Monoclonal antibody
Irinotecan liposome combined with bevacizumab is one of 34 small molecule programs targeting Glioma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
394 competitors in Glioma
#DrugCompanyPhaseTrials
1Paraplatin
AAvyxa
Phase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Bicnu
MMelissa K Accordino
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Velban
EEastern Cooperative Oncology Group
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Modeyso
CChimerix
Phase 3
Selumetinib /m2
NNational Cancer Institute (NCI)
Phase 3
Chemotherapeutic Agent
Day One BiopharmaceuticalsPhase 3
Luvometinib
SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZhifeng Tian,MD